telisotuzumab

Key facts

Mechanism of action

Hepatocyte growth factor receptor inhibitor

Primary target: Hepatocyte growth factor receptor

Approval history

1. M24-064 Phase 3 · AbbVie Deutschland GmbH · Metastatic Colorectal Cancer
2. M25-287 Phase 3 · AbbVie Deutschland GmbH · Non-Squamous Non-Small Cell Lung Cancer
3. M25-713 Phase 3 · AbbVie Deutschland GmbH · Non-Small Cell Lung Cancer
4. Telisotuzumab Adizutecan Phase 3 · AbbVie · Non-Small Cell Lung Cancer
5. Telisotuzumab Vedotin, DOCETAXEL Phase 3 · AbbVie Deutschland GmbH · c-Met overexpressing EGFR wildtype non-squamous non-small ce
6. M24-311 Phase 2 · AbbVie Deutschland GmbH · Colorectal Cancer
7. M24-533 Phase 2 · AbbVie Deutschland GmbH · Metastatic Colorectal Cancer
8. M24-536 Phase 2 · AbbVie Deutschland GmbH · Advanced or Metastatic Non-Squamous NSCLC

1. cabozantinib s-malate Hepatocyte growth factor receptor inhibitor
2. capmatinib hydrochloride Hepatocyte growth factor receptor inhibitor
3. tepotinib hydrochloride Hepatocyte growth factor receptor inhibitor
4. capmatinib Antineoplastic and immunomodulating agents (L01)
5. tepotinib Antineoplastic and immunomodulating agents (L01)
6. capmatinib hydrochloride hydrate Hepatocyte growth factor receptor inhibitor

Frequently asked questions